Evidence map›Paper›PMID 34276935›Full record

ArticleChemical science2021

Rapid and robust cysteine bioconjugation with vinylheteroarenes.

Hikaru Seki, Stephen J Walsh, Jonathan D Bargh, Jeremy S Parker, Jason Carroll, David R Spring

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Ultrafast Au(III)-Mediated Arylation of Cysteine.Journal of the American Chemical Society · 2024
    Article
  12. Article
  13. RSC chemical biology · 2023
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Hikaru SekiDepartment of Chemistry, University of Cambridge Lensfield Road Cambridge CB2 1EW UK spring@ch.cam.ac.uk.ORCID https://orcid.org/0000-0001-9663-7791
Stephen J WalshDepartment of Chemistry, University of Cambridge Lensfield Road Cambridge CB2 1EW UK spring@ch.cam.ac.uk.ORCID https://orcid.org/0000-0002-3164-1519
Jonathan D BarghDepartment of Chemistry, University of Cambridge Lensfield Road Cambridge CB2 1EW UK spring@ch.cam.ac.uk.ORCID https://orcid.org/0000-0003-3023-2569
Jeremy S ParkerEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca Macclesfield UK.ORCID https://orcid.org/0000-0002-4758-3181
Jason CarrollCancer Research UK Cambridge Institute, University of Cambridge Robinson Way Cambridge CB2 0RE UK.ORCID https://orcid.org/0000-0003-3643-0080
David R SpringDepartment of Chemistry, University of Cambridge Lensfield Road Cambridge CB2 1EW UK spring@ch.cam.ac.uk.ORCID https://orcid.org/0000-0001-7355-2824
University of Cambridge · GBAstraZeneca (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methods for residue-selective and stable modification of canonical amino acids enable the installation of distinct functionality which can aid in the interrogation of biological processes or the generation of new therapeutic modalities. Herein, we report an extensive investigation of reactivity and stability profiles for a series of vinylheteroarene motifs. Studies on small molecule and protein substrates identified an optimum vinylheteroarene scaffold for selective cysteine modification. Utilisation of this lead linker to modify a number of protein substrates with various functionalities, including the synthesis of a homogeneous, stable and biologically active antibody-drug conjugate (ADC) was then achieved. The reagent was also efficient in labelling proteome-wide cysteines in cell lysates. The efficiency and selectivity of these reagents as well as the stability of the products makes them suitable for the generation of biotherapeutics or studies in chemical biology.

Identifiers

PMID34276935
PMCPMC8261766
OpenAlexW3170448447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.